急性心肌梗死缺血/再灌注损伤的机制及其药物防治进展被引量：19

下载PDF

导出

摘要由于直接经皮冠脉介入术(percutaneous coronary intervention,PCI)和静脉溶栓的再灌注治疗能挽救濒死心肌、减少心肌梗死面积从而显著改善预后,因此被作为急性ST段抬高型心肌梗死(ST-segment elevation myocardial infarction,STEMI)患者的推荐治疗策略。然而,即使采取了早期再灌注治疗,STEMI患者1年的死亡率仍达10%。缺血/再灌注(ischemia/reperfusion,I/R)引发的心肌组织细胞损伤显著增加心肌梗死患者的死亡率和多种并发症,降低了急性心肌梗死(acute myocardial infarction,AMI)患者再灌注治疗的获益。近年来对于I/R损伤的分子和免疫学研究进展促进了与组织炎症和器官功能不全的治疗策略更新。本文就AMI的I/R损伤机制及其药物防治进展进行文献复习。

作者高翔宇李卫萍贺毅张晓洁邸北冰李虹伟

机构地区首都医科大学附属北京友谊医院心内科

出处《临床和实验医学杂志》 2019年第20期2237-2240,F0003,共5页 Journal of Clinical and Experimental Medicine

基金国家自然科学基金(编号:81300161) 首都医科大学附属北京友谊医院科研启动基金(编号:yyqdkt2017-34)

关键词急性心肌梗死心肌缺血再灌注损伤机制防治

分类号 R54 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献2

1Yuan-Yuan Cao Zhang-Wei Chen Yan-Hua Gao Xing-Xu Wang Jian-Ying Ma Shu-Fu Chang Ju-Ying Qian Jun-Bo Ge.Exenatide Reduces Tumor Necrosis Factor-α-induced Apoptosis in Cardiomyocytes by Alleviating Mitochondrial Dysfunction[J].Chinese Medical Journal,2015(23):3211-3218. 被引量：5
2Christiane Neuhof,Heinz Neuhof.Calpain system and its involvement in myocardial ischemia and reperfusion injury[J].World Journal of Cardiology,2014,6(7):638-652. 被引量：23

二级参考文献26

1Moe GW, Marin-Garcia J, Konig A, Goldenthal M, Lu X, Feng Q. In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol 2004;287:H1813-20.
2Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide I. Proc Natl Acad Sci U S A 1992;89:8641-5.
3Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, et al. Exenatide reduces infarct size and improves cardiac tanction in a porcine model ofischemia and reperfusion injury. J Am Coil Cardiol 2009;53:501-10.
4Chang G, Zhang D, L iu J, Zhang EYe L, Lu K, et al.Exenatide protects against hypoxia/reoxygenation-induced apoptosis by improving mitochondrial function in H9c2 cells. Exp Biol Med (Maywood) 2014;239:414-22.
5Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al. G LP-IR agonist l iraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-83.
6Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et aL Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion, Circulation 2004; 109:962-5.
7Lonborg J, Vejlstrup N, Kelbsek H, Botker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:1491-9.
8Simpson P, Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res 1982;50:101-16.
9Skyschally A, Gres P, Hoffmann S, Haude M, Erbel R, Schulz R, et al. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: Progressive contractile dysfunction versus delayed protection against infarction. Circ Res 2007;100:140-6.
10Schulz R, Aker S, Belosjorow S, Heusch G. TNFalpha in ischemia/ reperfusion injury and heart failure. Basic Res Cardiol 2004;99:8-11.